| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
ACBI1 targets SMARCA2 (BRM), SMARCA4 (BRG1), and PBRM1, which are subunits of the BAF (BRG1/BRM-associated factor) chromatin remodeling complex. As a PROTAC, it induces the degradation of these proteins by recruiting an E3 ubiquitin ligase, leading to their ubiquitination and proteasomal degradation. This results in anti-proliferative effects and apoptosis.
|
|---|---|
| ln Vitro |
ACBI1 exhibits anti-proliferative action at 1–10,000 nM over 3–7 days [1]. SK-MEL-5 cells undergo apoptosis when exposed to ACBI1 (0.3 µM; 100 hours) [1]. The E3 ubiquitin ligase von Hippel-Lindau, a linker, and a bromodomain ligand make up ACBI1[1].
In vitro, ACBI1 is a potent degrader of SMARCA2, SMARCA4, and PBRM1 in MV-4-11 cells with DC50 values of 6 nM, 11 nM, and 32 nM, respectively. It induces anti-proliferative effects and apoptosis in cancer cells. The compound shows synergistic activity in degrading multiple BAF complex subunits. |
| ln Vivo |
In vivo activity data for ACBI1 are not extensively detailed in the available sources. As a PROTAC degrader, it has potential for therapeutic applications in cancers driven by BAF complex dysregulation. Specific in vivo efficacy data are not provided.
|
| Enzyme Assay |
The in vitro protein degradation assay for ACBI1 involves measuring the reduction in SMARCA2, SMARCA4, and PBRM1 protein levels. Cells (e.g., MV-4-11) are treated with ACBI1 at various concentrations for a defined period. Protein levels are quantified by Western blotting, and DC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell proliferation assay[1]
Cell Types: MV-4-11, NCI-H1568 Cell Tested Concentrations: 0-1000 nM Incubation Duration: 3-7 days Experimental Results: demonstrated anti-proliferative activity, IC50 of MV-4 is 29, 68 nM -11, NCI-H1568 cells. Apoptosis analysis[1] Cell Types: SK-MEL-5 Cell Tested Concentrations: 0.3 µM Incubation Duration: 100 hrs (hours) Experimental Results: Induction of apoptosis in SK-MEL-5 cells. Cellular assays are performed using MV-4-11 cells. Cells are treated with ACBI1 at various concentrations, and cell viability is assessed using assays such as MTT or CellTiter-Glo. Apoptosis is measured using Annexin V staining or caspase activity assays. Protein degradation is confirmed by Western blotting. |
| Animal Protocol |
In vivo animal studies for ACBI1 are not detailed in the available sources. As a PROTAC degrader, it is being investigated for its potential therapeutic applications, but specific animal models and dosing regimens are not described.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ACBI1 are not available in the provided sources. As a PROTAC molecule, it has a larger molecular weight (936.10 g/mol) and may have different PK properties compared to small molecule inhibitors. Specific PK parameters are not reported.
|
| Toxicity/Toxicokinetics |
Toxicity data for ACBI1 are not reported in the available sources. As an investigational compound, it is used for research purposes only.
|
| References | |
| Additional Infomation |
ACBI1 is a research tool for studying the BAF chromatin remodeling complex and its role in cancer. It is a PROTAC degrader that induces protein degradation rather than enzymatic inhibition. The compound is available from chemical suppliers for research use only.
|
| Molecular Formula |
C49H58FN9O7S
|
|---|---|
| Molecular Weight |
936.1043
|
| Exact Mass |
935.416
|
| Elemental Analysis |
C, 62.87; H, 6.25; F, 2.03; N, 13.47; O, 11.96; S, 3.42
|
| CAS # |
2375564-55-7
|
| Related CAS # |
ACBI1 HCl;2375564-55-7;
|
| PubChem CID |
137628619
|
| Appearance |
White to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1144.1±65.0 °C at 760 mmHg
|
| Flash Point |
645.7±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.684
|
| LogP |
2.45
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
67
|
| Complexity |
1650
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=C(SC=N1)C2=CC(=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)C4(CC4)F)O)OCCOC5=CC=C(C=C5)CN6CCN(CC6)C7=CC(=NN=C7N)C8=CC=CC=C8O
|
| InChi Key |
IVARZBJJMMUJHI-SQKKEFIPSA-N
|
| InChi Code |
InChI=1S/C49H58FN9O7S/c1-30-42(67-29-53-30)32-11-12-33(26-52-45(62)39-24-34(60)28-59(39)46(63)43(48(2,3)4)54-47(64)49(50)15-16-49)41(23-32)66-22-21-65-35-13-9-31(10-14-35)27-57-17-19-58(20-18-57)38-25-37(55-56-44(38)51)36-7-5-6-8-40(36)61/h5-14,23,25,29,34,39,43,60-61H,15-22,24,26-28H2,1-4H3,(H2,51,56)(H,52,62)(H,54,64)/t34-,39+,43-/m1/s1
|
| Chemical Name |
(2S,4R)-N-[[2-[2-[4-[[4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]methyl]phenoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2S)-2-[(1-fluorocyclopropanecarbonyl)amino]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide
|
| Synonyms |
ACBI1; ACBI-1; ACBI 1;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~106.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0683 mL | 5.3413 mL | 10.6826 mL | |
| 5 mM | 0.2137 mL | 1.0683 mL | 2.1365 mL | |
| 10 mM | 0.1068 mL | 0.5341 mL | 1.0683 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
